SEC Company Response from PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — May 25, 2016
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: May 25, 2016 · CIK: 0001095981 · Accession: 0001140361-16-066958
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210628
Letter
May 25, 2016
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549-4561
Attn: Ms. Ravitz
Mr. Buchmiller
Mr. Jones
Re: Cytori Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-210628
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Cytori Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Thursday, May 26, 2016, or as soon thereafter as practicable.
The Company acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please contact Jeffrey Baglio of DLA Piper LLP (US) with any questions or comments at (858) 677-1458. Thank you for your assistance with this filing.
Very truly yours,
Cytori Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm May 25, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-4561 Attn: Ms. Ravitz Mr. Buchmiller Mr. Jones Re: Cytori Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-210628 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Cytori Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Thursday, May 26, 2016, or as soon thereafter as practicable. The Company acknowledges that: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, such declaration does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please contact Jeffrey Baglio of DLA Piper LLP (US) with any questions or comments at (858) 677-1458. Thank you for your assistance with this filing. Very truly yours, Cytori Therapeutics, Inc. By:a /s/ Tiago Girão Name: Tiago Girão Title: Chief Financial Officer